Background A poor ability of recommended risk scores for predicting in-hospital bleeding has been reported in elderly patients with acute coronary syndromes (ACS). No study assessed the prediction of post-discharge bleeding in the elderly. The new BleeMACS score (Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary Syndrome), was designed to predict postdischarge bleeding in ACS patients. We aimed to assess the predictive ability of the BleeMACS score in elderly patients. Methods We assessed the incidence and characteristics of severe bleeding after discharge in ACS patients aged ! 75 years. Bleeding was defined as any intracranial bleeding or bleeding leading to hospitalization and/or red blood transfusion, occurring within the first year after discharge. We assessed the predictive ability of the BleeMACS score according to age by Fine-Gray proportional hazards regression analysis, calculating receiver-operating characteristic (ROC) curves and the area under the ROC curves (AUC).
Introduction
Dual antiplatelet therapy (DAPT) with aspirin and an oral P2Y12 receptor blocker is the standard regimen to prevent atherothrombotic events in patients after acute coronary syndromes (ACS).
1,2 Antiplatelet drugs decrease the rate of ischaemic events in patients with ACS, but with a significant increase in the rate of bleeding. 3 There is strong evidence about the association between bleeding complications and increased mortality in this scenario. 4 Therefore, bleeding risk is the limiting factor for the choice of the type and duration of DAPT after discharge in patients with ACS. While several bleeding scores [5] [6] [7] have been developed and widely used for the prediction of in-hospital bleeding, little information exists about the prediction of bleeding after discharge in this setting. The BleeMACS registry 8 (Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary Syndrome) was conducted to develop and validate a score to predict postdischarge bleeding in patients with ACS. This score exhibited a good ability for predicting serious bleeding 1 year after discharge in an extensive series of patients with ACS. On the other hand, incidence of ACS increases with age, and it is particularly high in elderly patients. 9, 10 These patients are at higher risk both for ischaemic and bleeding complications, prolonged hospital stay and increased consumption of health resources. 11 Elderly are poorly represented in clinical trials and registries from whom currently recommended bleeding risk scores were developed. In fact, a poorer predictive ability of these bleeding risk scores for predicting in-hospital bleeding has been reported in elderly patients with ACS. 12 To our knowledge, no study assessed the prediction of post-discharge bleeding in elderly patients with ACS. Therefore, the aim of this sub-study was to analyse, in the BleeMACS database, the incidence and characteristics of bleeding complications after medical discharge according to age, and to assess the predictive ability of the BleeMACS score in elderly patients as compared with the younger population.
Methods
This study is a sub-analysis of the international multi-centre BleeMACS registry. Full study protocol has been already published. 13 In brief, the BleeMACS registry enrolled 15,401 consecutive patients undergoing percutaneous coronary intervention (PCI) for ACS, including ST-elevation myocardial infarction (STEMI), non-STEMI (NSTEMI) and unstable angina (UA). Recruitment was conducted between 2003 and 2014 in 15 hospital centres from 10 countries from North America (Canada), South America (Brazil), Europe (Germany, Poland, Netherlands, Spain, Italy, Greece) and Asia (China and Japan). DAPT was prescribed during at least 12 months, except in patients treated with oral anticoagulants, in whom antiplatelet therapy was prescribed based on clinical judgment of the responsible physician. Baseline clinical characteristics, in-hospital procedures and adverse events were recorded for all patients.
A one-year follow-up after the discharge from index hospitalization was conducted and data about vital status, bleeding complications, cardiovascular events and other adverse events were collected from hospital records, by telephonic contact with patients or their relatives or their primary care physician if deemed necessary.
The primary end-point of the study was the incidence of serious bleeding complications within the first year after hospital discharge, defined as intracranial bleeding or any other bleeding leading to hospitalization and/or red blood cell transfusion. Bleeding and/or red blood transfusions related to procedures or surgeries were not considered for the purpose of this study.
The BleeMACS score 8 was compound by seven independent predictors of bleeding (age, hypertension, vascular disease, history of bleeding, malignancy, creatinine and haemoglobin). The score was developed by assigning a weighted integer to each independent predictor on the basis of its coefficient in the final model. A point score for each patient was calculated by summing the weighted integers (►Table 1). Patients were classified further into quartiles of the BleeMACS risk score: very low-risk ( 7 points), low-risk (8-16 points), moderaterisk (17-24 points) and high-risk (! 25 points). This risk score exhibited a good ability for predicting spontaneous serious bleeding after discharge (c-statistic value of 0.71 in the derivation cohort and 0.72 in the internal validation sample).
Definitions
NSTEMI was defined as the presence of chest pain in the previous 48 hours accompanied by electrocardiographic Conclusion Elderly patients with ACS had a significantly higher incidence of postdischarge bleeding. Despite a lower predictive ability in older patients, the BleeMACS score exhibited an acceptable performance in these patients.
abnormalities suggestive of ischaemia or blood troponin value above the higher normal laboratory limit. STEMI was defined as chest pain with persistent ST-segment elevation of 0.1 mV or more in at least two contiguous leads or new left bundle branch block in the electrocardiogram. Hypertension was defined as prior history of diagnosed and/or treated hypertension. Vascular disease included prior stroke/transient ischaemic attack, and/or peripheral artery disease (in the external validation dataset, vascular disease was defined as stroke and/or peripheral artery disease, because data on transient ischaemic attack were not available). Malignancy was defined as any active cancer or any non-active cancer treated during the past 3 years of the index ACS. History of bleeding included any hospitalization due to a bleeding event prior to the qualifying ACS and/or any serious bleeding occurring during hospitalization for the index ACS. For the purpose of this study, elderly patients were defined as patients aged 75 years or older.
Statistical Analysis
Categorical variables were expressed as number and percentage. Quantitative variables were expressed as mean and standard deviation. The variables with non-normal distribution were expressed as median and interquartile range. Analysis of the normality of the distribution was conducted by the Kolmogorov-Smirnoff test. Comparisons between categorical variables were performed with the chi-square test or Fisher's exact test, when appropriate. Comparisons between quantitative variables were performed with the Student's t-test.
The performance of the BleeMACS risk score was assessed using the Fine-Gray proportional hazards regression analysis, 14 using a competing risk framework for bleeding occurrence-accounting for death as a competing episode. The proportional hazard assumption was confirmed by testing for time-by-covariate interaction in the multivariate analysis, and the adjusted hazard of bleeding was expressed as sub-hazard ratios (sHRs) with their corresponding 95% confidence intervals (95% CIs). The adjusted rate of 1-year bleeding was calculated and reported as cumulative incidence function (CIF).
Additionally, the ability of the BleeMACS score for predicting the composite of post-discharge serious bleeding or death was assessed by a Cox regression model.
The performance of the BleeMACS score according to age status was tested assessing its discrimination separately in elderly patients and young patients from the BleeMACS database. Discrimination was evaluated by calculating the area under the receiver-operating characteristic (ROC) curve (AUC), and by assessing CIF curves between the four established BleeMACS score risk categories. The AUCs between elderly and young patients were compared using the DeLong method.
15 A two-sided p-value equal to or less than 0.05 was considered as statistically significant. Finally, a predictive model for post-discharge bleeding was built specifically in patients aged 75 years or older. This analysis was also performed using the Fine-Gray proportional hazards regression model, considering death as a competing episode. Variables included in the multivariate analysis were those with an association (p < 0.05) with bleeding in univariate analysis. The best model was selected taking into account the criteria of the best AUC.
All analyses were undertaken using the statistical software PASW Statistics 18 and the STATA 14.1 version.
Results
The BleeMACS registry included 15,401 patients, of whom 11,809 (76.7%) were male. Mean age was 63.6 (AE12.7) years, and 3,376/15,401 patients (21.9%) were aged 75 years or older. The characteristics of patients according to age are shown in ►Table 2.
Patients aged 75 years or older were less often males and had a higher prevalence of cardiovascular risk factors and other comorbidities, such as previous stroke, malignancy or previous bleeding. These patients had significantly lower glomerular filtration and lower haemoglobin values at admission as compared with younger patients. In addition, clinical presentation with STEMI was less common in the elderly. Older patients had also poorer left ventricular ejection fraction and more severe coronary artery disease as compared with the rest of the patients. Bleeding complications, need for transfusion, heart failure and reinfarction during hospitalization were more common in patients aged 75 years or older.
Significant differences were also observed regarding postdischarge antithrombotic treatment according to age subgroups (►Table 3). Elderly patients were more commonly treated with clopidogrel and less often treated with ticagrelor or prasugrel. Oral anticoagulants were more commonly prescribed in the elderly. Triple therapy was also more commonly used in older patients. Beta-blockers and statins were less commonly used in older patients. No significant differences were observed regarding the use of angiotensinconverting enzyme (ACE) inhibitors or angiotensin receptor (AR) blockers.
Post-Discharge Bleeding
During 1-year follow-up, 489/15,401 patients (3.2%) presented serious spontaneous bleeding. The incidence of bleeding episodes was moderately higher in elderly patients (HR, 2.31, 95% CI, 1.92-2.77, p < 0.001, ►Fig. 1). 
Clinical Characteristics and Antithrombotic Management According to Post-Discharge Bleeding in Elderly Patients
Clinical characteristics according to post-discharge bleeding status in elderly patients are shown in ►Table 4. Some comorbidities such as congestive heart failure, malignancy and previous bleeding were more common in patients who presented post-discharge bleeding. These patients had worse Killip class at admission, lower left ventricular ejection fraction and more severe coronary artery disease. In addition, patients with post-discharge bleeding had lower haemoglobin value at admission, poorer renal function and higher incidence of inhospital bleeding and need for transfusion.
On the other hand, post-discharge use of clopidogrel was less common and use of ticagrelor was more common in patients who presented post-discharge 1 year bleeding episodes. No significant differences were observed regarding the post-discharge use of the rest of treatments (►Table 5).
Predictive Ability According to Age
The ability of the BleeMACS score for predicting post-discharge bleeding was moderately lower in elderly patients as compared with the rest (AUC, 0.652 [95% CI, 0.624-0.679] vs. 0.691 [95% Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DAPT, dual antiplatelet therapy; OAC, oral anticoagulant; PPI, proton pump inhibitor; SAPT, single antiplatelet therapy. 
Prediction of Bleeding in the Elderly
The best model for predicting bleeding in elderly patients included hypertension, previous bleeding, haemoglobin at admission and previous heart failure. This model showed an Finally, ►Table 6 shows the specific contribution of each component of the BleeMACS score for predicting post-discharge bleeding according to age. The contribution of age, vascular disease and malignancy was not statistically significant in elderly patients. In contrast, the predictive role of hypertension, previous bleeding, renal function and haemoglobin levels remained significant in both sub-groups.
Discussion
The main findings from our study are: (1) elderly patients from this series patients had a moderately higher incidence of serious spontaneous bleeding at 1 year and a shorter time to bleeding episodes, without significant differences regarding bleeding location; and (2) despite a moderately lower predictive ability in patients at older ages, the BleeMACS score showed an acceptable performance in these patients.
Haemorrhagic complications are associated with a higher mortality in patients with ACS, especially in the elderly.
16-18
Current guidelines establish a reference standard duration of DAPT of 12 months.
2 However, recent evidence suggests that treatment with DAPT beyond the first year may be beneficial in selected groups of patients with low bleeding risk,
19
particularly when the ischaemic risk is high. 20 On the other hand, guidelines state that shorter DAPT regimens may be considered in patients deemed at high bleeding risk.
2 Therefore, bleeding risk is one of the main factors in choosing the type and duration of antiplatelet therapy after an ACS. Several bleeding risk scores have been developed and widely used for predicting major in-hospital bleeding.
5-7 These recommended risk scores seem to not adequately predict post-discharge bleeding in patients with ACS. 21 The bleeding profile for in-hospital phase (predominance of access site bleeding, related with the coronary intervention and parenteral antithrombotic drugs) is clearly different than for post-discharge period (predominance of gastrointestinal bleeding, related with oral antiplatelet therapy). [22] [23] [24] Recent studies have demonstrated that bleeding after discharge is also associated with a significant increase in the risk of death and myocardial infarction.
25-27
Available information about the prediction of bleeding after discharge in patients with ACS is scarce. Baber et al 19 developed a risk score for predicting major bleeding at 2 years in 4,190 patients undergoing successful PCI with stent implantation from the PARIS registry. Independent predictors of bleeding included older age, body mass index, triple therapy at discharge, anaemia, current smoking and renal dysfunction, and the predictive model showed an acceptable ability for predicting major bleeding. In a sub-study of the Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DAPT, dual antiplatelet therapy; OAC, oral anticoagulant; PPI, proton pump inhibitor; SAPT, single antiplatelet therapy. It is important to note that patients included in these studies were at relatively low bleeding risk, since more than 60% of patients from the PARIS registry 19 underwent PCI for stable angina, and in a not negligible proportion of patients included in the PRECISE-DAPT score and in the DAPT study,
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the reason for performing PCI was not an ACS. In addition, patients suffering bleeding events during the first 12 months on DAPT and patients requiring oral anticoagulation were not included in the DAPT study. The BleeMACS score 8 was the first risk score designed to estimate the probability of developing a serious haemorrhagic event within the first year after hospital discharge for an ACS. The score was developed in an extensive series of all corners ACS patients from routine clinical practice, obtaining a good predictive ability in this clinical setting. On the other hand, the incidence of ACS is particularly high in the elderly, and the number of elderly patients who are hospitalized for ACS is increasing. 9, 10 These patients are at increased risk both for ischaemic and bleeding complications. However, information about the real incidence of post-discharge bleeding in non-selected elderly patients with ACS from routine clinical practice is scarce. Data from this series showed a higher incidence of post-discharge bleeding in elderly patients. However, this increase of risk was moderate, despite the clearly higher prevalence of comorbidities of patients at older ages. On the other hand, a poorer ability of the recommended risk scores for predicting in-hospital bleeding in elderly patients with ACS has previously been reported. 12, 29, 30 The prediction of bleeding after discharge in patients at older ages is also an important issue, since the antithrombotic management of these patients is often complex, due to a more severe and complex coronary artery disease, higher prevalence of comorbidities and more common concomitant indication of oral anticoagulants because of conditions such as atrial fibrillation or previous stroke. To date, no study assessed the prediction of post-discharge bleeding episodes in elderly patients with ACS. The ability of the BleeMACS score for predicting postdischarge bleeding was lower in patients aged 75 years or older from this series. However, this loss of performance was moderate, in contrast to other studies assessing in-hospital bleeding risk in elderly patients. 12 The lower predictive ability observed in elderly patients from our study could be mostly due to the fact that age accounts for more than 10% of points of the total score. Despite this, in our opinion the BleeMACS score exhibited an acceptable performance also in elderly patients. In fact, the predictive model specifically performed in elderly patients did not significantly improve the prediction of bleeding as compared with the BleeMACS score. Interestingly, the predictive role of each of the components of the score differed according to age. While several predictors remained significant or increased its level of significance in the elderly (renal function, haemoglobin, hypertension, previous bleeding), others reduced its predictive contribution to the model (age, vascular disease, malignancy). A different antithrombotic management in patients with these conditions or different types of neoplasm at older ages (not so aggressive or with a lower likelihood for bleeding) may partially explain these findings. However, the type of neoplasm was not recorded in the BleeMACS database, so these data should be confirmed in other populations.
Aging is a heterogeneous process and risk assessment in elderly patients might be conditioned by the presence of frailty and other aging-related variables. [31] [32] [33] Recent data suggest a modest contribution of a comprehensive geriatric assessment for predicting in-hospital bleeding in elderly patients with ACS. 34 However, the role of these variables for predicting bleeding after discharge could be more important.
This article has several limitations. The BleeMACS score was derived from a cohort of a retrospective registry, carrying the limitations inherent to this type of studies. Changes in antithrombotic therapy were not assessed, such as switch between antiplatelet drugs or DAPT discontinuation. On the other hand, information about frailty, disability and other aging-related variables was not available. However, despite these limitations we believe that this article retrieves novel and important data about characteristics and prediction of bleeding complications after discharge in elderly patients with ACS from routine clinical practice.
Conclusions
Elderly patients from this series had a moderately higher incidence of post-discharge bleeding. In spite of a moderate loss of predictive ability in patients at older ages, the BleeMACS exhibited an acceptable performance also in these patients.
What is known about this topic?
• Elderly patients are at higher risk for ischaemic and bleeding complications, prolonged hospital stay and increased consumption of health resources.
• The elderly are poorly represented in clinical trials and registries from whom currently recommended bleeding risk scores were developed. A poorer ability of these risk scores for predicting in-hospital bleeding has been reported in elderly patients with ACS.
• Information about prediction of post-discharge bleeding is scarce. The BleeMACS score exhibited a good ability for predicting serious bleeding 1 year after discharge in non-selected patients with ACS. No study assessed the prediction of post-discharge bleeding in elderly patients with ACS.
What does this paper add?
• In this extensive series (n ¼ 15,401) of ACS patients, patients aged ! 75 years (21.9%) were more commonly treated with clopidogrel and less often treated with ticagrelor or prasugrel. A total of 489/15,401 patients (3.2%) presented serious spontaneous bleeding at 1 year. The incidence of bleeding was moderately higher in elderly patients (HR, 2.31, 95% CI, 1.92-2.77, p < 0.001).
• Mean time to bleeding episodes was significantly shorter in the elderly (134 vs. 159 days, p < 0.001), without significant differences regarding bleeding location according to age.
• Despite a moderate loss of predictive ability in patients at older ages (AUC, 0.652 vs. 0.691, p ¼ 0.001), the BleeMACS score exhibited an acceptable performance also in the elderly. The specific contribution of each of the components of the score was significantly different according to age.
